Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2015

View Archived Issues

Genentech's LGR5-targeting ADC inhibits growth of colon cancer

SMRX-11: A clot-specific streptokinase

Novel CSF-1R inhibitor shows promising results for bone tumors

Italian and U.S. academic team patents ASAH1 inhibitors

AbbVie patents V1bR ligands

Chengdu Bestchiralbio announces DPP IV inhibitors

Roche reports anti-HBV agents

Eisai presents splicing factor 3B modulators

Calitor Sciences and Sunshine Lake Pharma present PI3K inhibitors

European Comission approves Horizon's Ravicti

Managed access program for ixazomib begins for patients with multiple myeloma

Heptares enters strategic drug discovery collaboration with Pfizer

Vericiguat holds promise for heart failure

Applications seeking approval of Stelara for Crohn's disease submitted by Janssen

Dose expansion implemented in study of immunomodulator EF-022 in patients with solid tumors

Phase I study of Intercept's INT-767 begins

FDA approves Empliciti for previously treated multiple myeloma

Novel kinase inhibitor shows promise for the treatment of HCC

Valneva releases data from phase II study of prophylactic C. difficile vaccine candidate

Phase III results for MD-1003 in MS patients with chronic visual loss following optic neuritis

Almirall to acquire dermatology specialist Poli Group

Puma Biotechnology reports plans for neratinib MAA filing

Roche licenses Proximagen VAP-1 inhibitor for inflammatory disease

Baxalta's Adynovate launched for the treatment of hemophilia in adult patients

Mallinckrodt closes sale of CMDS business to Guerbet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...